MCM
ESPR

Manchester Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Manchester Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-180
Closed -$477 – 1391
2025
Q3 		$477 Hold
180
– – ﹤0.01% 1203
2025
Q2 		$178 Hold
180
– – ﹤0.01% 1176
2025
Q1 		$260 Hold
180
– – ﹤0.01% 1121
2024
Q4 		$396 Hold
180
– – ﹤0.01% 1090
2024
Q3 		$297 Sell
180
-270
-60% -$545 ﹤0.01% 1117
2024
Q2 		$999 Buy
+450
New +$1.06K ﹤0.01% 1007

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Manchester Capital Management's ESPR Position: Q4 2025 in Review

Manchester Capital Management sold out of Esperion Therapeutics (ESPR) in Q4 2025, closing a stake of 180 shares — an estimated $477 sold.

Manchester Capital Management first reported a position in ESPR in Q2 2024 and held it in 6 quarters. The position peaked at $999 in Q2 2024. 200 funds tracked by Wall St. Rank hold ESPR as of Q4 2025.

  • Manchester Capital Management reported no remaining Esperion Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Manchester Capital Management sold 180 Esperion Therapeutics shares in Q4 2025, an estimated $477.
  • Manchester Capital Management first reported a position in Esperion Therapeutics in Q2 2024 and held it in 6 quarters.
  • Manchester Capital Management's Esperion Therapeutics position peaked at $999 in Q2 2024.
  • 200 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2025.

Based on Manchester Capital Management's 13F filing for Q4 2025, filed 11 Feb 2026.